A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.

Trial Details

NCT ID
NCT06775275
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Adebellizumab
  • Bevacizumab
  • Platinum-based chemotherapy
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Resectable NSQ NSCLC
  • Age 18-65 years
  • male or female
  • Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →